rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

American Shared Hospital Services

AMS · NYSE American

Health CareDiagnostics & Labs

We hold no 150-day reading for AMS yet: it needs about 200 sessions of history. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+2 points in four weeks); Health Care: 27% (−6 points in four weeks).

Statistics

Last close, 23 Oct 2026
1.26 0.00%
52-week range
—
Volume
0.00M
Average volume (50 days)
—
Relative volume
—
Rotation
not in the set
Weeks in an uptrend
—
Industry in uptrend
52% +2 in 4 wk
Insider buys, 12 months
$2.7M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
19 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.

24 Apr – 23 Oct
20%37%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Price and volume

$1.23$1.35$1.4811 Sep23 Sep5 Oct14 Oct23 Oct
close

Daily bars to 23 Oct 2026: 30 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.6MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Raymond C. StachowiakExecutive Chairmanbought586,468at $2.2822 Jun 2026filed 24 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders19+0 on the quarter
New · exited5 · 5
Reported value$800K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026102,140$161K-102,980−50.2%
LPL Financial LLCadded · filed 7 Aug 202681,386$129K+5,020+6.6%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 202657,695$91K+8,495+17.3%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202655,662$88K-98,075−63.8%
JAMES INVESTMENT RESEARCH, INC.unchanged · filed 24 Jul 202629,725$47K00.0%
NewEdge Advisors, LLCunchanged · filed 12 Aug 202629,725$47K00.0%
BRIDGEWAY CAPITAL MANAGEMENT, LLCreduced · filed 14 Aug 202629,124$46K-61,696−67.9%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202626,497$42K-6,091−18.7%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 202625,363$40K-2,043−7.5%
XTX Topco Ltdnew · filed 14 Aug 202619,107$30K+19,107
31 Mar 2023 – 30 Jun 2026
121620Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Raymond C. Stachowiak Company insiderExecutive Chairman · last 22 Jul 20264 · 0
Craig Kenji Tagawa Company insiderPresident · last 30 Apr 20250 · 8
Raymond Scott Frech Company insiderChief Financial Officer · last 19 Dec 20240 · 0
Gary Delanois Company insiderChief Operating Officer · last 14 Oct 20240 · 0
Robert L. Hiatt Company insiderChief Financial Officer · last 17 Apr 20230 · 0
Peter M. Gaccione Company insiderChief Executive Officer · last 28 Mar 20230 · 0
Ernest Robert Bates Company insiderSr.VP Sales and Business Devel · last 1 Apr 20220 · 0
Kathleen Miles Company insiderDirector · last 28 Dec 20210 · 0
Vicki L. Wilson Company insiderDirector · last 28 Dec 20210 · 0
Daniel G. Kelly, Jr. Company insiderDirector · last 25 Jun 20210 · 0
David Larson Company insiderDirector · last 25 Jun 20210 · 2
Saim Mert Ozyurek Company insiderDirector · last 25 Jun 20210 · 0

Same industry

No other stock in its industry this week.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202518.0%
Operating profit marginFY 2025 · to 31 Dec 2025-12.8%
Free cash flow marginFY 2025 · to 31 Dec 2025-16.2%
Return on capital employedFY 2025 · to 31 Dec 2025-11.2%
Debt to equityFY 2025 · to 31 Dec 20251.44×
Interest coverFY 2025 · to 31 Dec 2025-2.28×
Share count trendFY 2025 · to 25 Mar 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.5M
Free cash flowFY 2025 · to 31 Dec 2025−$4.5M

Analyst forecasts

No analyst forecasts yet.